Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Table 1

Clinical information of 33 advanced colorectal cancer patients (n = 33).

Characteristics	Statistics
Sex (male/female)	15/18
Age (years)	53.64 ± 10.34
ECOG (0/1)	10/23
Primary tumor location (left/right)	23/10
Liver metastases (yes/no)	20/13
Lung metastases (yes/no)	28/5
Lymph node metastasis (yes/no)	22/11
Excision of primary lesion (yes/no)	29/4
Number of previous chemotherapy lines
(2/3 lines or above)	16/17
Regorafenib (80 mg/120 mg)	23/10
KRAS genetic testing (yes/no)	21/12
KRAS (wild/mutation)	13/8
Previous chemotherapeutic drug
Fluorouracil (yes/no)	33/0
Oxaliplatin (yes/no)	33/0
Irinotecan (yes/no)	33/0
Raltitrexed (yes/no)	12/21
Previously targeted drugs
Bevacizumab (yes/no)	28/5
Cetuximab (yes/no)	11/22

ECOG, Eastern Cooperative Oncology Group performance status.